Qualigen Therapeutics, Inc. — Director's Dealing 2021

Dec 10, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Qualigen Therapeutics, Inc. (QLGN)
CIK: 0001460702
Period of Report: 2021-12-08

Reporting Person: BROIDRICK AMY S. (Director, President/ChiefStrategyOfficer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-12-08	Stock Option (Right to Buy)	$1.24	A	300000	Acquired	2031-12-08	Common Stock (300000)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	4500	Direct

Footnotes

F1: Shares underlying the stock option vest over three years in three equal annual installments from the date of grant.